✦ LIBER ✦

Systemic sclerosis disease modification clinical trials design: Quo vadis?

✍ Scribed by Fabian A. Mendoza; Lynette L. Keyes-Elstein; Sergio A. Jimenez

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Disease modification in multiple scleros

✍ Richard A. Rudick 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 185 KB

Current concepts in disease-modifying th

✍ Karen Au; Dinesh Khanna; Philip J. Clements; Daniel E. Furst; Donald P. Tashkin 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 388 KB

Disease modification and other trials in

✍ Janet E. Pope; Dinesh Khanna; Sindhu R. Johnson; Phil Clements 📂 Article 📅 2012 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 61 KB

P-194: Modification of the staggered sta

✍ Suzanne Hendrix; Alexander Gutin; Kenton Zavitz; Graham Carron; Mark Laughlin; S 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 190 KB

P-196: A mathematical comparison of a “r

✍ Scott Horton; Alexander Gutin; Suzanne Hendrix 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Design of a randomized clinical trial wi

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 58 KB